A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)
Public ClinicalTrials.gov record NCT00642460. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Placebo-controlled Study to Evaluate the Effect of Tocilizumab on Disease Response in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA), With an Open-label Extension to Examine the Long Term Use of Tocilizumab
Study identification
- NCT ID
- NCT00642460
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 112 participants
Conditions and interventions
Conditions
Interventions
- tocilizumab [RoActemra/Actemra] Drug
- Placebo Drug
- Non-steroidal anti-inflammatory drugs (NSAIDs) Drug
- methotrexate Drug
- corticosteroids Drug
Drug
Eligibility (public fields only)
- Age range
- 2 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2008
- Primary completion
- Aug 31, 2009
- Completion
- Jul 31, 2014
- Last update posted
- Jul 24, 2016
2008 – 2014
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Little Rock | Arkansas | 45229-3039 | — |
| Not listed | Los Angeles | California | 90027 | — |
| Not listed | Hartford | Connecticut | 06106 | — |
| Not listed | Augusta | Georgia | 30912 | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Louisville | Kentucky | 40202-3906 | — |
| Not listed | Hackensack | New Jersey | 07601 | — |
| Not listed | Livingston | New Jersey | 07039 | — |
| Not listed | Durham | North Carolina | 27710 | — |
| Not listed | Cincinnati | Ohio | 45229 | — |
| Not listed | Cleveland | Ohio | 44195 | — |
| Not listed | Oklahoma City | Oklahoma | 73104 | — |
| Not listed | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00642460, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 24, 2016 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00642460 live on ClinicalTrials.gov.